Search
September 17-20, 2025
Toronto, Ontario, Canada
This year the International Myeloma Society is bringing global multiple myeloma experts in Toronto to brainstorm, reflect, challenge, and advance our shared understanding in understanding the complex underlying disease biology.
Veeda Lifesciences is excited to be part of the momentum. We can’t wait to engage in power packed sessions – industry symposiums and present abstracts with insights from our latest Multiple Myeloma Trials.
Let’s connect because we’ve got a lot to share.
Maintenance Therapy
Innovative MRD Techniques
Combination Therapies
Frontline Therapy
Bispecific T-cell Engagers
Antibody-Drug Conjugates
Monoclonal Antibodies
Proteasome Inhibitors
Immunomodulatory Drugs
More than two decades ago, a multiple myeloma diagnosis offered little hope. But today, thanks to ground-breaking science and relentless collaboration, we’re witnessing remarkable progress. Still, the road is long and battle against the disease continues to present pressing challenges.
We are committed to bring innovation to life and transform patient outcomes. With an indepth expertise across a broad spectrum of registrational trials, we have aimed to support therapies that offer hope across every stage of the patient journey.
Expert insights into the latest advancements, evolving treatment strategies, and the future of care for patients
Accelerate clinical trials with Veeda Lifesciences. From patient recruitment to regulatory guidance, we deliver efficient solutions for faster approvals.
Supporting Hemato-Oncology Trials Through Our Multi-layered Approach